Ensol Biosciences (XKRX:140610) COGS-to-Revenue : 0.01 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences COGS-to-Revenue?

Ensol Biosciences's Cost of Goods Sold for the six months ended in Dec. 2024 was ₩12 Mil. Its Revenue for the six months ended in Dec. 2024 was ₩1,435 Mil.

Ensol Biosciences's COGS to Revenue for the six months ended in Dec. 2024 was 0.01.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ensol Biosciences's Gross Margin % for the six months ended in Dec. 2024 was 99.17%.

Ensol Biosciences COGS-to-Revenue Historical Data

The historical data trend for Ensol Biosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences COGS-to-Revenue Chart

Ensol Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.69

0.13

0.27

0.01

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial						0.28	0.69	0.13	0.27	0.01

Ensol Biosciences COGS-to-Revenue Calculation

Ensol Biosciences's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.975	/	1434.621
	=	0.01

Ensol Biosciences's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.975	/	1434.621
	=	0.01

Ensol Biosciences (XKRX:140610) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ensol Biosciences's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	11.975 / 1434.621
	=	99.17 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Ensol Biosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines